Suppr超能文献

鉴定肺腺癌对 HSP90 抑制剂反应的预测性生物标志物。

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma.

机构信息

H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Hospital 12 de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain.

CIBERONC, Respiratory Tract Tumors Program, 28029 Madrid, Spain.

出版信息

Int J Mol Sci. 2021 Mar 3;22(5):2538. doi: 10.3390/ijms22052538.

Abstract

Heat shock protein 90 (HSP90) plays an essential role in lung adenocarcinoma, acting as a key chaperone involved in the correct functioning of numerous highly relevant protein drivers of this disease. To this end, HSP90 inhibitors have emerged as promising therapeutic strategies, even though responses to them have been limited to date. Given the need to maximize treatment efficacy, the objective of this study was to use isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic techniques to identify proteins in human lung adenocarcinoma cell lines whose basal abundances were correlated with response to HSP90 inhibitors (geldanamycin and radicicol derivatives). From the protein profiles identified according to response, the relationship between lactate dehydrogenase B (LDHB) and DNA topoisomerase 1 (TOP1) with respect to sensitivity and resistance, respectively, to geldanamycin derivatives is noteworthy. Likewise, rhotekin (RTKN) and decaprenyl diphosphate synthase subunit 2 (PDSS2) were correlated with sensitivity and resistance to radicicol derivatives. We also identified a relationship between resistance to HSP90 inhibition and the p53 pathway by glucose deprivation. In contrast, arginine biosynthesis was correlated with sensitivity to HSP90 inhibitors. Further study of these outcomes could enable the development of strategies to improve the clinical efficacy of HSP90 inhibition in patients with lung adenocarcinoma.

摘要

热休克蛋白 90(HSP90)在肺腺癌中发挥着重要作用,作为一种关键伴侣蛋白,它参与了许多与该疾病密切相关的蛋白驱动因子的正常功能。为此,HSP90 抑制剂已成为很有前途的治疗策略,尽管迄今为止它们的反应受到限制。鉴于需要最大限度地提高治疗效果,本研究的目的是使用基于等重同位素标记相对和绝对定量(iTRAQ)的蛋白质组学技术,鉴定与人肺腺癌细胞系中与 HSP90 抑制剂(格尔德霉素和雷地霉素衍生物)反应相关的蛋白。根据对这些抑制剂的反应来识别蛋白图谱,我们注意到乳酸脱氢酶 B(LDHB)和 DNA 拓扑异构酶 1(TOP1)与对格尔德霉素衍生物的敏感性和耐药性之间存在相关性。同样,Rhotekin(RTKN)和二磷酸胞苷二磷酸香叶醇合成酶亚基 2(PDSS2)与对雷地霉素衍生物的敏感性和耐药性相关。我们还发现 HSP90 抑制与葡萄糖剥夺引起的 p53 通路之间存在相关性。相比之下,精氨酸生物合成与 HSP90 抑制剂的敏感性相关。对这些结果的进一步研究可以为改善 HSP90 抑制剂在肺腺癌患者中的临床疗效制定策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8955/7962034/703ba6b0138c/ijms-22-02538-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验